Showing 5391-5400 of 5956 results for "".
- Envision Announces Dates, Calls for Submissions for 2020 Conferenceshttps://modernod.com/news/envision-announces-dates-calls-for-submissions-for-2020-conferences/2477082/Envision announced that it is now accepting submissions for clinical education and research presentations for its two annual conferences in 2020: Envision Conference West, April 3-4, UT Health San Antonio Department of Occupational Therapy in San Antonio, Texas; and Envision Conference East, Augu
- Novaliq and Jiangsu Hengrui Medicine Announce a Collaboration for Investigational NOV03 and CyclASol in Chinahttps://modernod.com/news/novaliq-and-jiangsu-hengrui-medicine-announce-a-strategic-collaboration-in-ophthalmology-for-the-eyesol-based-investigational-products-nov03-and-cyclasol-in-china/2477080/Novaliq and Jiangsu Hengrui Medicine, a biopharmaceutical company based in China, announced the closing of an exclusive license agreement to develop, manufacture and commercialize water-free drugs NOV03 and CyclASol for the treatment of dry eye disease in the People’s Republic of China (including
- Ocular Therapeutix Announces Strategic Update and Operational Restructuringhttps://modernod.com/news/ocular-therapeutix-announces-strategic-update-and-operational-restructuring/2477081/Ocular Therapeutix announced an operational restructuring plan that the company says is expected to result in an estimated $11 million in annualized savings through personnel reductions and approximately $14 million in one-time program deferrals. The company estimates that it will record costs as
- Optina Diagnostics and Wagner Macula Retina Center to Conduct a Study to Identify the Causes of Memory Loss Through Eye Diagnosticshttps://modernod.com/news/optina-diagnostics-and-wagner-macula-retina-center-will-collaborate-to-conduct-a-clinical-study-to-identify-the-causes-of-memory-loss-through-eye-diagnostics/2477076/Optina Diagnostics and Wagner Macula Retina Center are entering into a collaboration agreement to conduct a clinical study for the advancement of Optina’s Retinal Deep Phenotyping platform. This collaboration will lay the groundwork for Optina’s future pivotal clinical trial. &
- Ocuphire Pharma Announces Results from Two Phase 2 Clinical Studies of Nyxol Eye Dropshttps://modernod.com/news/ocuphire-pharma-announces-results-from-two-phase-2-clinical-studies-of-nyxol-eye-drops/2477075/Ocuphire Pharma announced statistically significant and clinically meaningful results from its recently completed two phase 2b studies of its lead drug candidate, Nyxol Eye Drops. Topline results of the primary and secondary endpoints of the MIRA-1 and ORION-1 studies provided confirmatory
- AGTC Announces Stargardt Disease as its Second Preclinical Ophthalmology Programhttps://modernod.com/news/agtc-announces-stargardt-disease-as-its-second-preclinical-ophthalmology-program/2477071/Applied Genetic Technologies Corporation (AGTC), announced that it has identified Stargardt disease as the second ophthalmology program in its previously announced preclinical pipeline expansion, which also includes a program targeting the dry form of age-related macular degenerat
- Aerie Pharmaceuticals Announces Positive Topline Results for Netarsudil in Phase 2 Study Conducted in Japanhttps://modernod.com/news/aerie-pharmaceuticals-announces-positive-topline-results-for-netarsudil-in-phase-2-study-conducted-in-japan/2477069/Aerie Pharmaceuticals reported positive topline results for the company’s phase 2 clinical trial evaluating netarsudil ophthalmic solution in Japanese patients. Netarsudil is a Rho kinase (ROCK) inhibitor specifically designed to increase outflow of aqueous humor through the trabecular meshwork,
- Allergan Issues Recall for Certain Lots of Xen 45https://modernod.com/news/allergan-issues-recall-for-certain-lots-of-xen-45/2477061/Allergan has initiated a voluntary recall of its XEN 45 glaucoma drainage device after a small number of units in an unreleased lot were observed to have trace amounts of polishing compounds that are used in the needle sleeve manufacturing process, according to a joint news release with ASCRS.
- Johnson & Johnson Vision Launches Tecnis Eyhance Monofocal IOL in Indiahttps://modernod.com/news/johnson-johnson-vision-launches-tecnis-eyhance-monofocal-iol-in-india/2477059/Johnson & Johnson Vision announced the launch of Tecnis Eyhance IOL, which is designed to extend depth of focus from distance to intermediate vision. Over the past several decades, India’s eye care system has made tremendous strides towards high q
- Manufacturers, Providers Increasingly Rely on Premium Cataract Surgery Revenuehttps://modernod.com/news/manufacturers-providers-increasingly-rely-on-premium-cataract-surgery-revenue/2477057/The importance of premium cataract surgery to manufacturers, surgeons, and surgery centers alike grows, as reimbursements for cataract surgery under nationalized health care systems worldwide continue to decline, according to a Market Scope report. The reduction in cataract surgery reimbur